Metastatic Hormone-Sensitive Prostate Cancer: Is Docetaxel Really Needed? Researchers suggest simpler ADT+ASI as default therapy - MedPage Today, by Jeff Minerd, Contributing Writer, October 6, 2022.
Seems not everyone agrees that up-front chemo is a good idea for mHSPC patients; i.e.:
"Recent clinical trial evidence has shown the benefit of triplet therapy -- androgen-deprivation therapy (ADT), docetaxel, and an androgen signaling inhibitor (ASI) -- in men with metastatic hormone-sensitive prostate cancer. But authors of a "Comments and Controversies" article in the Journal of Clinical Oncology asked whether docetaxel is truly needed, or whether ADT with an ASI might be the best option for most patients, sparing them toxicity."
No clinical trials have compared ADT plus an ASI head-to-head with ADT and docetaxel in these patients. However, recent subgroup and meta-analyses have provided some suggestive evidence, said Francisco Vera-Badillo, MD, of Queen's University in Kingston, Ontario, and Adi Kartolo, MD, of McMaster University in Hamilton, Ontario, who co-authored the article with Ian F. Tannock, MD, PhD, DSc, of Princess Margaret Cancer Centre of the University of Toronto.
In the following interview, Vera-Badillo and Kartolo elaborated on that evidence and discussed the implications."
(See link below for the full interview)
An Alternative to Triplet Therapy for Metastatic Hormone-Sensitive Prostate Cancer
– Francisco Vera-Badillo, MD, and Adi Kartolo, MD, suggest simpler ADT+ASI as default therapy, by Jeff Minerd , Contributing Writer, MedPage Today October 6, 2022
medpagetoday.com/reading-ro...
The full article is here:
Management of Metastatic Hormone-Sensitive Prostate Cancer: Is Docetaxel Needed?
– An ASCO Reading Room selection, October 6, 2022, Adi Kartolo, MD; Ian F. Tannock, MD, PhD, DSc; and Francisco E. Vera Badillo, MD, MSc, Journal of Clinical Oncology
ascopubs.org/doi/10.1200/JC...
And additional comment here:
In Lower-Volume Metastatic Hormone-Sensitive Prostate Cancer, Is Added Docetaxel Needed? – The addition of docetaxel should likely be reserved for patients who may need it the most, by Rajasree Pia Chowdry, MD, MedPage Today, ASCO > Prostate Cancer, October 6, 2022,
medpagetoday.com/reading-ro...
The controversy rages while patients do their job as test mules. Understand the options and choose wisely. Most importantly, Be Safe and Stay Well,
Paz - K9 terror